Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

MIAMI BEACH -- The surgical dogma favoring axillary dissection in breast cancer continues to give way to more selective data-driven strategies that allow more women to avoid axillary surgery, an ...

Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis. This ...

Women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer who have one positive sentinel node and no high-risk features can likely be spared ...

Targeted axillary dissection (TAD) is a relatively new breast cancer procedure. It allows surgical oncologists to specifically locate a lymph node that contained cancer before chemotherapy, remove it ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no detrimental effect on outcomes in most cases, continuing a trend toward less ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Omission of completion axillary lymph node dissection did not increase recurrence among patients ...

Previous trials have shown that omission of axillary-lymph-node dissection does not appear to affect important outcomes. New research findings extend those findings and are summarized in a short video ...